ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1792

CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus

Lauren Robinson1, Preetha Balasubramanian2, Zurong Wan2, Juan Rodriguez Alcazar2, Marina Lima Silva Santos2, Lynnette Walters3, Jeanine Baisch2, Karen Onel4, Tracey Wright5, Virginia Pascual6 and Simone Caielli2, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Scottish Rite Hospital for Children, Allen, TX, 4HSS, New York, NY, 5UT Southwestern, Plano, TX, 6Weill Cornell Medical College, New York, NY

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), Biomarkers, interferon, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature. It is widely known that patients with SLE often have Coombs positivity, but the presence of anti-erythrocyte autoantibodies in the absence of hemolytic anemia has long been thought to be clinically insignificant. Recently, these antibodies have been proposed to play a pathogenic role in childhood-onset SLE (cSLE) via opsonization of mitochondria-containing erythrocytes and induction of type-I IFN production by myeloid cells in-vitro (Caielli et al., 2021). In this study we investigated whether peripheral myeloid cells from children with SLE demonstrate evidence of subclinical erythrocyte uptake.

Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from cSLE (n=20) and healthy children (n=4). PBMCs were stained for lineage surface markers prior to fixation and permeabilization followed by intracellular staining for the erythrocyte membrane protein CD235a. Intracellular positivity was measured by flow cytometry. Subsequently, PBMC samples from a well-characterized longitudinal cohort of children with SLE were screened for the presence of CD235a+ monocytes.

Results: A subset of patients with cSLE display intracellular CD235a positivity within blood monocytes, which is absent in healthy children (Figure 1). CD235a intracellular positivity is most prevalent within CD14+ monocytes and did not correlate with clinical measures of anemia.  Preliminary results from the longitudinal cohort suggest a correlation between frequency of blood CD235a+ CD14+ monocytes and disease activity per the SLEDAI-2K over time in a subset of patients.

Conclusion: This study confirms the presence of subclinical erythrocyte uptake within peripheral myeloid cells of patients with childhood-onset SLE in the absence of anemia. Future work will focus on the longitudinal nature of the anti-erythrocyte response in children with SLE with a specific focus on immunological phenotyping of the peripheral CD14+ monocytes demonstrating erythrocyte uptake.

Supporting image 1

Figure 1: A) representative flow plots from a patient with SLE and a pediatric healthy control gated on all monocytes demonstrating CD235a positivity in CD14+ monocytes from the patient with SLE. B) The percentage of CD235a+ among CD14+ monocytes in patients with SLE (n=20) vs HC (n=4), p value determined by kruskal wallis test.


Disclosures: L. Robinson: None; P. Balasubramanian: None; Z. Wan: None; J. Rodriguez Alcazar: None; M. Lima Silva Santos: None; L. Walters: None; J. Baisch: None; K. Onel: None; T. Wright: None; V. Pascual: AstraZeneca, 5, Merck/MSD, 2, Novartis, 9; S. Caielli: None.

To cite this abstract in AMA style:

Robinson L, Balasubramanian P, Wan Z, Rodriguez Alcazar J, Lima Silva Santos M, Walters L, Baisch J, Onel K, Wright T, Pascual V, Caielli S. CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cd14-monocytes-demonstrate-subclinical-erythrocyte-uptake-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd14-monocytes-demonstrate-subclinical-erythrocyte-uptake-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology